Evidence supporting the use of: Immunoglobulins
For the health condition: Multiple Sclerosis

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Intravenous immunoglobulins (IVIg) have been investigated as a treatment option for multiple sclerosis (MS), particularly for patients who are unable to use first-line disease-modifying therapies (DMTs) or during pregnancy and breastfeeding. Scientific studies have shown that IVIg can have immunomodulatory effects, potentially reducing relapse rates in relapsing-remitting MS (RRMS). Several randomized controlled trials conducted in the 1990s and early 2000s suggested modest benefits of IVIg, such as decreased relapse rates and delayed disability progression in RRMS patients. A 2004 Cochrane review concluded that IVIg may reduce the risk of relapses in RRMS, but the effect size was small and evidence quality was moderate. However, subsequent larger and more rigorous studies failed to confirm significant long-term benefits, and IVIg is generally considered less effective than approved first-line DMTs like interferon-beta or glatiramer acetate. Major guidelines, including those from the American Academy of Neurology and the European Committee for Treatment and Research in Multiple Sclerosis, do not recommend IVIg as a standard treatment for MS, except in select cases where other therapies are contraindicated or not tolerated. In summary, while there is scientific evidence supporting the use of immunoglobulins in MS, the magnitude of benefit is limited, and its use is generally reserved for special circumstances rather than as a primary therapy.

More about Immunoglobulins
More about Multiple Sclerosis

Products containing Immunoglobulins

We currently have no products on Caring Sunshine that contain this ingredient.